Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase III study of maintenance therapy with TS-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus TS-1 for advanced or relapsed squamous cell carcinoma of the lung

Trial Profile

A randomized phase III study of maintenance therapy with TS-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus TS-1 for advanced or relapsed squamous cell carcinoma of the lung

Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2019

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Carboplatin
  • Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2019 Primary endpoint (Progression free survival from the date of randomization for maintenance therapy) has been met as per results published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2019 Results published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology
    • 22 Mar 2019 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top